Pandemic Pulse

A combination between AstraZeneca and the first component of Sputnik V vaccine (Sputnik Light) demonstrates high immunogenicity profile in the clinical study in Azerbaijan

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), AstraZeneca and R-Pharm announce preliminary results on immunogenicity of combined use of the AstraZeneca vaccine (developed jointly with the University of Oxford) and the first component of the Sputnik V vaccine (Sputnik Light vaccine based on human adenovirus serotype 26) from the clinical trial of […]